DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pseudoxanthoma elasticum", "PXE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aflibercept; CAS No.: 7758-16-9; Disodium Pyrophosphate; Eylea; Intravitreal injection ranibizumab; LANSOPRAZOLE; Lansolprazole; Lansoprazole; Lansoprazole 30mg; Lucentis; Magnesium; Magnesium Oxide; Magnesium oxide; Pyrophosphate; RANIBIZUMAB; RFB002; RFB002, rhuFab V2; RFB002A; Ranibizumab; Ranibizumab injection (0.5 mg); RhuFab V2; SODIUM ACID PYROPHOSPHATE; SODIUM ACID PYROPHOSPHATE SAPP ROR 28 FOOD GRADE

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02537054 (ClinicalTrials.gov)	September 2015	21/8/2015	Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)	Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)	Pseudoxanthoma Elasticum	Drug: Aflibercept	University Hospital, Bonn	NULL	Completed	18 Years	65 Years	All	15	Phase 2	Germany
2	EUCTR2014-005263-33-DE (EUCTR)	29/04/2015	26/02/2015	Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum	Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP	Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: Eylea	Medizinische Fakultät der Universität Bonn	NULL	Not Recruiting			Female: yes Male: yes	15	Phase 2	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02537054
(ClinicalTrials.gov)

September 2015

21/8/2015

Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)

Pseudoxanthoma Elasticum

Drug: Aflibercept

University Hospital, Bonn

NULL

Completed

18 Years

65 Years

All

Phase 2

Germany

EUCTR2014-005263-33-DE
(EUCTR)

29/04/2015

26/02/2015

Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum

Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP

Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]

Trade Name: Eylea

Medizinische Fakultät der Universität Bonn

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Germany